Brokerages Set Pluristem Therapeutics Inc. (PSTI) Price Target at $3.83

Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) have been assigned a consensus recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $3.83.

Several research analysts have recently weighed in on PSTI shares. HC Wainwright set a $4.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Monday, December 17th. Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Saturday, February 9th. Finally, Maxim Group set a $3.00 price objective on shares of Pluristem Therapeutics and gave the company a “buy” rating in a report on Monday, December 17th.

Pluristem Therapeutics stock remained flat at $$0.63 during trading hours on Monday. 583,390 shares of the company’s stock traded hands, compared to its average volume of 466,425. The stock has a market capitalization of $73.83 million, a PE ratio of -2.50 and a beta of 1.32. Pluristem Therapeutics has a twelve month low of $0.56 and a twelve month high of $1.52.

Pluristem Therapeutics (NASDAQ:PSTI) last released its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $0.05 million for the quarter. As a group, analysts predict that Pluristem Therapeutics will post -0.28 earnings per share for the current year.

In related news, CEO Yaky Yanay acquired 71,429 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was purchased at an average cost of $0.70 per share, with a total value of $50,000.30. Following the completion of the acquisition, the chief executive officer now directly owns 4,253,045 shares of the company’s stock, valued at $2,977,131.50. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.20% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Van ECK Associates Corp grew its position in Pluristem Therapeutics by 38.7% during the fourth quarter. Van ECK Associates Corp now owns 50,443 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 14,087 shares during the period. Virtu Financial LLC grew its position in Pluristem Therapeutics by 266.1% during the first quarter. Virtu Financial LLC now owns 85,104 shares of the biotechnology company’s stock valued at $83,000 after buying an additional 61,858 shares during the period. Jane Street Group LLC grew its position in Pluristem Therapeutics by 337.4% during the third quarter. Jane Street Group LLC now owns 94,023 shares of the biotechnology company’s stock valued at $122,000 after buying an additional 72,526 shares during the period. ETF Managers Group LLC grew its position in Pluristem Therapeutics by 49.6% during the fourth quarter. ETF Managers Group LLC now owns 250,848 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 83,207 shares during the period. Finally, B. Riley Financial Inc. bought a new stake in Pluristem Therapeutics during the third quarter valued at approximately $320,000. Institutional investors own 5.39% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Read More: Call Option Volume

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.